Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 3Recruiting 2Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Endometrial Neoplasms 4Anorexia 3Weight Loss 2Cachexia 2Body Weight 2Squamous Intraepithelial Lesions 1Recurrence 1Pancreatic Neoplasms 1Overweight 1Obesity 1Neoplasms 1Lung Neoplasms 1Infertility 1Breast Neoplasms 1Body Weight Changes 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Megestrol Acetate × Clear all
NCT00637806 2016-05-02

Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

Par Pharmaceutical, Inc.

Phase 3 Terminated
4 enrolled 6 charts

Anorexia, Body Weight, Cachexia, Neoplasms, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡